BI 2536

Catalog No.S1109

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Price Stock Quantity  
USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
USD 997 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

BI 2536 Chemical Structure

BI 2536 Chemical Structure
Molecular Weight: 521.66

Validation & Quality Control

Cited by 50 publications:

10 customer reviews :

Quality Control & MSDS

Related Compound Libraries

PLK Inhibitors with Unique Features

  • Selective Plk Inhibitors

    GSK461364 Plk1-selective, Ki=2.2 nM.

  • Plk Inhibitor in Clinical Trial

    Rigosertib (ON-01910) Phase III for Myelo Dysplastic Syndrome (MDS).

  • Newest Plk Inhibitor

    Ro3280 Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

  • Calssic Plk Inhibitor

    Volasertib (BI 6727) Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

Product Information

  • Compare PLK Inhibitors
    Compare PLK Products
  • Research Area
  • Inhibition Profile
  • BI 2536 Mechanism

Product Description

Biological Activity

Description BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.
Targets PLK1 [1]
(Cell-free assay)
PLK2 [1]
(Cell-free assay)
PLK3 [1]
(Cell-free assay)
PI3Kα [1]
(Cell-free assay)

 View  More

IC50 0.83 nM 3.5 nM 9.0 nM 2.407 μM
In vitro BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. [1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
PSN1NXLJbHVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTBwMEC3O|Yh|ryPNH3CWW9USU6JRWK=
ACNM1H4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHP4dmVKSzVyPUCuNFA5PDNizszNMl[0V2FPT0WU
TE-8NVjtN4EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjKTWM2OD1yLkCwPVQyKM7:TR?=M{TEdnNCVkeHUh?=
LC-2-adMkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLXTWM2OD1yLkCxNFk{KM7:TR?=NH\vVY5USU6JRWK=
ALL-PONEfXWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDaTWM2OD1yLkCxN{DPxE1?Mnz3V2FPT0WU
EW-16M2raXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTBwMEGzN|Yh|ryPMV\TRW5ITVJ?
KM12NYHBNGo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzNVlBKSzVyPUCuNFE{PDhizszNMWjTRW5ITVJ?
GI-1NE\vZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDFTWM2OD1yLkCxN|g{KM7:TR?=M1no[XNCVkeHUh?=
LS-411NMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTBwMEG0NFch|ryPM2\NRXNCVkeHUh?=
ES8NHvLV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjIW2liUUN3ME2wMlAyPDl2IN88US=>MXPTRW5ITVJ?
SNU-C2BNVLOR2dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\Kc2JOUUN3ME2wMlAyPTJ4IN88US=>Mlf5V2FPT0WU
CESSNGTkXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXKT41SUUN3ME2wMlAyPjB{IN88US=>M1;pPHNCVkeHUh?=
697M1Tq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfUVFRKSzVyPUCuNFE3PjhizszNM4TQVnNCVkeHUh?=
NCI-H1963M3K3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XicGlEPTB;MD6wNVY4OyEQvF2=NV3Se5lkW0GQR1XS
IA-LMNE[wWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\PbpJKSzVyPUCuNFE3QDhizszNMYjTRW5ITVJ?
SW954M2nRT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPJb3hKSzVyPUCuNFE4ODVizszNNFfUNVZUSU6JRWK=
RL95-2NVv5VVFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DF[mlEPTB;MD6wNVc{QCEQvF2=NHLPfpdUSU6JRWK=
LXF-289M2mxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXk[mhKSzVyPUCuNFE4PyEQvF2=MV\TRW5ITVJ?
OCUB-MNHnrR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzlTWM2OD1yLkCxPFI3KM7:TR?=MV7TRW5ITVJ?
RKONETxeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3DSpRKSzVyPUCuNFE6QDdizszNM2fISnNCVkeHUh?=
LOUCYNVK5XVhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vWc2lEPTB;MD6wNlA2KM7:TR?=M3W1dnNCVkeHUh?=
NOS-1Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInVV2lKSzVyPUCuNFIxQTNizszNNIHlN4FUSU6JRWK=
A4-FukMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHH4N|lKSzVyPUCuNFIzOThizszNM2jje3NCVkeHUh?=
A388M4[xVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTBwMEKyNlch|ryPMYfTRW5ITVJ?
TE-9NHr2[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnjdZlKSzVyPUCuNFIzPjFizszNMmj6V2FPT0WU
KURAMOCHINVuxNnM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTBwMEKyPFUh|ryPNXPBXHM2W0GQR1XS
KALS-1NUK4ZVNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVi3eI5QUUN3ME2wMlAzOzN6IN88US=>NXG3[mZiW0GQR1XS
HOP-62MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTBwMEK0NkDPxE1?NFXPdHlUSU6JRWK=
RPMI-8402M4LzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zEb2lEPTB;MD6wNlUxQCEQvF2=M2CyXnNCVkeHUh?=
TE-1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDJe|NXUUN3ME2wMlAzPTF{IN88US=>MW\TRW5ITVJ?
CCRF-CEMM4TKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVn5Z3NvUUN3ME2wMlAzPTR|IN88US=>NYWwWIJrW0GQR1XS
HUTU-80NX;FbmdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVG5XmY4UUN3ME2wMlAzPjJ2IN88US=>NXPz[HdMW0GQR1XS
NCI-H1648MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TmOGlEPTB;MD6wNlY1PyEQvF2=NFHHeo9USU6JRWK=
HCE-4Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnYXoVbUUN3ME2wMlAzPjh{IN88US=>NVK2RpRtW0GQR1XS
ETK-1NF3vdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vtcmlEPTB;MD6wNlc{PiEQvF2=NV;IbZZSW0GQR1XS
TE-15NY\u[I52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXFTWM2OD1yLkCyO|M5KM7:TR?=M2XVN3NCVkeHUh?=
BE-13MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LiNmlEPTB;MD6wNlc1KM7:TR?=M2r0RXNCVkeHUh?=
KE-37MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTBwMEK3OFEh|ryPM3LPWXNCVkeHUh?=
NCI-H1355NWHyd|FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mkf5TWM2OD1yLkCyO|g{KM7:TR?=M2ixW3NCVkeHUh?=
TE-11MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXhTWM2OD1yLkCyPFA6KM7:TR?=M1PS[HNCVkeHUh?=
BL-70NUTxVmZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTBwMEK4OVch|ryPMYDTRW5ITVJ?
ES6NXvuWVFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLYO29KSzVyPUCuNFI5QDFizszNMVXTRW5ITVJ?
GT3TKBMmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;FTJdKSzVyPUCuNFI6PTNizszNNHPsTGFUSU6JRWK=
LB647-SCLCMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDwVHBKSzVyPUCuNFMyQTVizszNNELLOnJUSU6JRWK=
NB13NV;vUGZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3oZnFHUUN3ME2wMlA{OzF4IN88US=>NFz3PIdUSU6JRWK=
ST486MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrUcWRKSzVyPUCuNFM{OzdizszNMnz0V2FPT0WU
NCI-H82NXToUlhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvWZ5N{UUN3ME2wMlA{OzR|IN88US=>NIDTOGhUSU6JRWK=
NTERA-S-cl-D1MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDK[WlKSzVyPUCuNFM{QTlizszNM1zBRnNCVkeHUh?=
ES4M37kTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHUU2h6UUN3ME2wMlA{PDZ|IN88US=>NIHTWHFUSU6JRWK=
SK-NEP-1NIHHPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4m4cWlEPTB;MD6wN|Q6QSEQvF2=Mn61V2FPT0WU
BeckerMkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrzfHhLUUN3ME2wMlA{PTV3IN88US=>NFfz[pVUSU6JRWK=
A101DNYPFUWhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlflTWM2OD1yLkCzO|Q5KM7:TR?=Ml32V2FPT0WU
SK-UT-1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF:5bllKSzVyPUCuNFM4PzRizszNM3\1fXNCVkeHUh?=
SW982MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlqwTWM2OD1yLkCzO|kh|ryPMn3zV2FPT0WU
TE-10MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTBwMESwOFYh|ryPMl7IV2FPT0WU
OVCAR-4M{jYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTBwMESwOVkh|ryPM1zN[3NCVkeHUh?=
KP-N-YSNGTnbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF[0eZNKSzVyPUCuNFQxQDVizszNNVjMR5RvW0GQR1XS
BL-41NWLzOlNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTBwMESxNlUh|ryPMX7TRW5ITVJ?
MZ1-PCNYrrPGJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHWxRpJKSzVyPUCuNFQyOjdizszNNEXI[otUSU6JRWK=
PF-382MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTyTWM2OD1yLkC0NVk5KM7:TR?=MUTTRW5ITVJ?
MOLT-13MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHNV3dKSzVyPUCuNFQzOzhizszNNX7jenBJW0GQR1XS
HCC1599NFqwcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rMUmlEPTB;MD6wOFI2QCEQvF2=MULTRW5ITVJ?
IST-MEL1NF\6[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjGV3p{UUN3ME2wMlA1PDR{IN88US=>NH7DT2lUSU6JRWK=
LU-139MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXNTWM2OD1yLkC0OFQzKM7:TR?=NH\0VYlUSU6JRWK=
MS-1MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPCXI94UUN3ME2wMlA1PzBzIN88US=>MWjTRW5ITVJ?
MFH-inoMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjoW3VEUUN3ME2wMlA2ODB|IN88US=>M13pXHNCVkeHUh?=
IMR-5M2XDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TKPGlEPTB;MD6wOVAzOSEQvF2=M4[5UHNCVkeHUh?=
TE-5MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fKZmlEPTB;MD6wOVA3OyEQvF2=M12yWXNCVkeHUh?=
DJM-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnP5TWM2OD1yLkC1NVQzKM7:TR?=MYjTRW5ITVJ?
NB17MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTBwMEWyNFch|ryPM3XBenNCVkeHUh?=
KARPAS-45NH\KNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVPXO2RtUUN3ME2wMlA2OzV6IN88US=>MlflV2FPT0WU
TGBC1TKBM3Pocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTBwMEW0NFUh|ryPMmLJV2FPT0WU
ML-2MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYexN2ZrUUN3ME2wMlA2PDF2IN88US=>M{XVNHNCVkeHUh?=
no-10NWjHU3FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7aSWRKSzVyPUCuNFU1PzRizszNM2TrdnNCVkeHUh?=
CTV-1NViwZ4JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvkTWM2OD1yLkC1OVAzKM7:TR?=Mo\MV2FPT0WU
SJSA-1MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTBwMEW1NkDPxE1?MoG4V2FPT0WU
HC-1NUDJWpY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\C[IU3UUN3ME2wMlA2PTl5IN88US=>MX7TRW5ITVJ?
TE-12NF7ZelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LpcWlEPTB;MD6wOVYyOyEQvF2=NWHjcldSW0GQR1XS
KY821NHeyZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDyNZNKSzVyPUCuNFU3OzJizszNMWTTRW5ITVJ?
TALL-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV24UopZUUN3ME2wMlA2PzB6IN88US=>NYjZc|dVW0GQR1XS
DELNIjGc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2i3[WlEPTB;MD6wOVcxQSEQvF2=MUHTRW5ITVJ?
TE-6M4X1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHZVoZKSzVyPUCuNFU4OjJizszNNIfRU5JUSU6JRWK=
SK-LMS-1NITRb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jJWGlEPTB;MD6wOVgxPSEQvF2=NHzwem1USU6JRWK=
EW-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIP2VGFKSzVyPUCuNFU5OzdizszNMl7OV2FPT0WU
8-MG-BAM2\0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fKSWlEPTB;MD6wOVg2OSEQvF2=NVPFdZpHW0GQR1XS
NALM-6Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDyTWM2OD1yLkC1PVc{KM7:TR?=NG[4S3RUSU6JRWK=
LB771-HNCMnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;GTWM2OD1yLkC1PVc6KM7:TR?=MUDTRW5ITVJ?
HT-144Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvxcZBKUUN3ME2wMlA3OTNizszNNUPRV2hkW0GQR1XS
KM-H2MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\kNo9KSzVyPUCuNFYzOjFizszNMYXTRW5ITVJ?
SF268NHLC[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3sO2Z6UUN3ME2wMlA3Ojh4IN88US=>MVrTRW5ITVJ?
RS4-11NYqyOFF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{WwTGlEPTB;MD6wOlMxPCEQvF2=NXzTWm15W0GQR1XS
MHH-PREB-1NXXKTZJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPJbJZKSzVyPUCuNFY{OTlizszNNILo[otUSU6JRWK=
ATN-1NFnJe3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHEV|hKSzVyPUCuNFY{PDVizszNM1n1bXNCVkeHUh?=
BB30-HNCMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTBwME[0N|Yh|ryPM{DUbXNCVkeHUh?=
CPC-NNFvNOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37ad2lEPTB;MD6wOlUzPCEQvF2=M1exeXNCVkeHUh?=
NB1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmraTWM2OD1yLkC2OlE{KM7:TR?=MYDTRW5ITVJ?
KS-1M3nzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTBwME[3OFgh|ryPNY[4cYNPW0GQR1XS
RXF393NYHieopsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTBwME[3OlQh|ryPMWHTRW5ITVJ?
IST-SL2MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HkUmlEPTB;MD6wO|AxPCEQvF2=MXTTRW5ITVJ?
GI-ME-NMo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PDTWlEPTB;MD6wO|I5PiEQvF2=MUXTRW5ITVJ?
VA-ES-BJMoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGOzSJJKSzVyPUCuNFc1PzVizszNMmT3V2FPT0WU
NCI-H1581NVvHfIJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\4WHhQUUN3ME2wMlA4PDd6IN88US=>MXjTRW5ITVJ?
U-266NX\ybHpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWH3TohmUUN3ME2wMlA4PDl5IN88US=>M4\xNXNCVkeHUh?=
DMS-114M3;TPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXjSPXVYUUN3ME2wMlA4PTJ6IN88US=>MWjTRW5ITVJ?
NCI-H187NETBe2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4[3XGlEPTB;MD6wO|czPiEQvF2=NUjWdVQ6W0GQR1XS
SW962MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4j6XWlEPTB;MD6wO|g{QSEQvF2=M2TvXnNCVkeHUh?=
MONO-MAC-6MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHm5dlFKSzVyPUCuNFc6QDZizszNNUH1NWdmW0GQR1XS
MOLT-16MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\sdFVKSzVyPUCuNFgyOjFizszNNYLldHhkW0GQR1XS
KNS-42M2rY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfVTWM2OD1yLkC4NVYyKM7:TR?=M2LUWXNCVkeHUh?=
CMKNVP4VnZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTBwMEiyNlUh|ryPNUjKWItPW0GQR1XS
Ramos-2G6-4C10NGH0ToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUL3PVZGUUN3ME2wMlA5OjJ3IN88US=>NHTTW|ZUSU6JRWK=
DaudiMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrxTWM2OD1yLkC4NlU3KM7:TR?=M1L3W3NCVkeHUh?=
NCI-H510AMlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPoSIw1UUN3ME2wMlA5OzN4IN88US=>MWrTRW5ITVJ?
LB831-BLCNGC4[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;KN2lEPTB;MD6wPFU3OSEQvF2=MmDjV2FPT0WU
HELNW\6b|RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorKTWM2OD1yLkC4OlY5KM7:TR?=NXOwfVBLW0GQR1XS
LU-134-AMnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\vcpU5UUN3ME2wMlA5PzB6IN88US=>MmqxV2FPT0WU
NCI-H1694NVvj[YNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XhfGlEPTB;MD6wPFc1PCEQvF2=MYPTRW5ITVJ?
KGNM{\WNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfm[llKSzVyPUCuNFg4PTlizszNM2PNXXNCVkeHUh?=
A253MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXwTFNOUUN3ME2wMlA5QDJ{IN88US=>M2Pu[XNCVkeHUh?=
DG-75NHnDWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonmTWM2OD1yLkC4PVIzKM7:TR?=NGjKOG5USU6JRWK=
MOLT-4NF3KeYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTBwMEi5PFMh|ryPMX;TRW5ITVJ?
NCI-SNU-5Mn7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTBwMEmyOVgh|ryPMorhV2FPT0WU
ONS-76MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTBwMEmyO|Yh|ryPNUPucIE3W0GQR1XS
NCI-H446MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\0cpVLUUN3ME2wMlA6PDZ{IN88US=>MXvTRW5ITVJ?
COR-L279NVuyUXVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmC4TWM2OD1yLkC5OVU3KM7:TR?=M3;MRXNCVkeHUh?=
Calu-6NIrXXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfjTWM2OD1yLkC5OVk5KM7:TR?=NGHteYNUSU6JRWK=
BC-3M2PPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTBwMEm2OlIh|ryPNVX5PHJZW0GQR1XS
NCI-H2126NWfBNGp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH:zbIJKSzVyPUCuNFk4QTFizszNNXridVg6W0GQR1XS
NCI-H1882NE\XSohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fTV2lEPTB;MD6wPVgxQSEQvF2=NF[xZ41USU6JRWK=
BB65-RCCMmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDpOIdKSzVyPUCuNVAzQTRizszNM{SxcHNCVkeHUh?=
DU-4475M2\UZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{i4VGlEPTB;MD6xNFQxPyEQvF2=MlPGV2FPT0WU
NCI-H526NIC4TFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;0PW5IUUN3ME2wMlExPDRizszNM1LISXNCVkeHUh?=
NEC8M3zrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13MZWlEPTB;MD6xNFUzPSEQvF2=Mm\MV2FPT0WU
NCI-H1304NI\ofHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnBPYdKSzVyPUCuNVA2QTRizszNNHjB[|dUSU6JRWK=
L-540NFjtZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTBwMUC3NFgh|ryPMn3GV2FPT0WU
NCI-SNU-16NITJeWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fTd2lEPTB;MD6xNFc1OiEQvF2=NVPHfFNzW0GQR1XS
HD-MY-ZMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnzU4djUUN3ME2wMlExQDV4IN88US=>MUPTRW5ITVJ?
K-562NIfMUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTBwMUC4OVgh|ryPNFTpNFBUSU6JRWK=
JARMlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzTR3IyUUN3ME2wMlExQTJ3IN88US=>NVfSVnJXW0GQR1XS
MZ2-MELNF7RO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTBwMUGwOUDPxE1?MYLTRW5ITVJ?
L-363NUe3XVdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjpdJJKSzVyPUCuNVExPzlizszNMkP1V2FPT0WU
BV-173MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn2wTWM2OD1yLkGxNlQ{KM7:TR?=NYPuXm5[W0GQR1XS
NCI-H524NF;qZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPidWlKSzVyPUCuNVEzPzRizszNM3fYZXNCVkeHUh?=
EoL-1-cellM1[4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTBwMUG2O|Ih|ryPNFWxc|ZUSU6JRWK=
K052NFKzcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmKyTWM2OD1yLkGxO|EzKM7:TR?=M1zZNnNCVkeHUh?=
TK10NHvVVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTBwMUG3Nlgh|ryPMXvTRW5ITVJ?
KU812MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIr4W4NKSzVyPUCuNVIxPDRizszNNIjNcFBUSU6JRWK=
RPMI-8226MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2ra[WlEPTB;MD6xNlA2OiEQvF2=NFqyV41USU6JRWK=
MZ7-melMlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLKTWM2OD1yLkGyNlM4KM7:TR?=MU\TRW5ITVJ?
SK-PN-DWMkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTBwMUKyPFch|ryPM373dnNCVkeHUh?=
SRMonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmi2TWM2OD1yLkGyOFQyKM7:TR?=M3XsNXNCVkeHUh?=
RPMI-6666MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTBwMUK3OFMh|ryPM{HKbnNCVkeHUh?=
no-11M1PWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmO4TWM2OD1yLkGyPFY6KM7:TR?=M{HOdHNCVkeHUh?=
EW-3NYr1bllsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XpZ2lEPTB;MD6xNlg6OyEQvF2=NIS2[VdUSU6JRWK=
LAMA-84MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPmW4x6UUN3ME2wMlE{OTh5IN88US=>MWTTRW5ITVJ?
HTNEnKNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LCT2lEPTB;MD6xN|U4PCEQvF2=Moq3V2FPT0WU
KP-N-RT-BM-1MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HMZ2lEPTB;MD6xN|YyOiEQvF2=NWDiRnRoW0GQR1XS
NCI-H747MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTBwMUO3JO69VQ>?NFz1dJZUSU6JRWK=
NCCITMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTBwMUO5N|kh|ryPM1HB[nNCVkeHUh?=
MLMAMnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTBwMUSxOlch|ryPNHW5XHJUSU6JRWK=
LP-1MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPvTWM2OD1yLkG0NlQh|ryPM{Due3NCVkeHUh?=
CAL-148Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\idpdKSzVyPUCuNVQ1QDNizszNNXz2SZM5W0GQR1XS
GB-1NGXX[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mkm1TWM2OD1yLkG0OVI3KM7:TR?=MVLTRW5ITVJ?
COR-L88NGnMRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTBwMUS4NFIh|ryPNXrNSXR7W0GQR1XS
NKM-1NFLBfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTBwMUS5NFYh|ryPMX3TRW5ITVJ?
NB5NXvSWYtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2j2bmlEPTB;MD6xOVQ3OiEQvF2=M1T3fXNCVkeHUh?=
SH-4NYjpbJpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTBwMUW0OlYh|ryPNV33e4RZW0GQR1XS
EM-2NEnWVmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1O4[GlEPTB;MD6xOVQ3PyEQvF2=MUDTRW5ITVJ?
TGBC24TKBMl\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTudnFSUUN3ME2wMlE2PjV7IN88US=>MWLTRW5ITVJ?
SCLC-21HMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnafHRKSzVyPUCuNVU4ODJizszNNXjV[G5nW0GQR1XS
COLO-684NHjLXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFv0SXJKSzVyPUCuNVU4OjFizszNMkXZV2FPT0WU
KINGS-1NVPmZ28yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vtU2lEPTB;MD6xOVkyKM7:TR?=NHH5dXlUSU6JRWK=
LS-123MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTBwMUW5NVch|ryPMYjTRW5ITVJ?
MC116MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MljHTWM2OD1yLkG2NVU5KM7:TR?=NYHL[WdCW0GQR1XS
SU-DHL-1MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfYZmlKSzVyPUCuNVYzODZizszNMoH1V2FPT0WU
NCI-H64MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTkTWM2OD1yLkG2N|Q4KM7:TR?=NFj4bYFUSU6JRWK=
HCE-TMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTBwMU[1NFQh|ryPNV2xZ2xpW0GQR1XS
LOXIMVINWrtTYtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vVcmlEPTB;MD6xOlk1QSEQvF2=MVHTRW5ITVJ?
ARH-77NVrDSJpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHBW3BKSzVyPUCuNVc{PzlizszNNFTBNZBUSU6JRWK=
DOHH-2NYXsWmdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE[3fXlKSzVyPUCuNVc3PzJizszNMoHoV2FPT0WU
COLO-320-HSRMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LLSWlEPTB;MD6xPFE2PCEQvF2=NXPvNZNZW0GQR1XS
NB6NIXRb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3rW5YxUUN3ME2wMlE5PTZ4IN88US=>NFu5[IFUSU6JRWK=
L-428NFTpWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFr5NFlKSzVyPUCuNVg5OTNizszNMVHTRW5ITVJ?
SNB75NX;mfm56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLBTWM2OD1yLkG4PFI1KM7:TR?=NFnoOIpUSU6JRWK=
NCI-H2141NWfxdVJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1eycmlEPTB;MD6xPVAyOSEQvF2=NUfkb5FrW0GQR1XS
KARPAS-299MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4i0S2lEPTB;MD6xPVI1OSEQvF2=MYjTRW5ITVJ?
LC4-1M1iyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7vWWpjUUN3ME2wMlE6PTB{IN88US=>MVvTRW5ITVJ?
UACC-257NFWzNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnnfWJKSzVyPUCuNVk6PDdizszNMnTSV2FPT0WU
EVSA-TMoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrqN5BpUUN3ME2wMlIxOzF{IN88US=>MnG0V2FPT0WU
JiyoyeP-2003MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGe0XmZKSzVyPUCuNlA1PzdizszNNGj1SlJUSU6JRWK=
NCI-H720MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTBwMkC1NlUh|ryPMmHGV2FPT0WU
GAKMoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIm3PYhKSzVyPUCuNlEyQDlizszNMUnTRW5ITVJ?
HHMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;vbWlEPTB;MD6yNVQxPSEQvF2=NEfScldUSU6JRWK=
NCI-H1436MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDSc|B3UUN3ME2wMlIyPDZ2IN88US=>M{DyOXNCVkeHUh?=
GR-STM3;JZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYP1ZnNzUUN3ME2wMlIyPDh6IN88US=>M2jpV3NCVkeHUh?=
BC-1NGr5Z2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTBwMkK2NVYh|ryPNHu1PJFUSU6JRWK=
SIG-M5NG\NfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULydI04UUN3ME2wMlIzPzJ5IN88US=>NVnGTWRDW0GQR1XS
NCI-H345NX7JTGVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\2d3pKSzVyPUCuNlM5ODVizszNMmr3V2FPT0WU
OPM-2M2jxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFztSlBKSzVyPUCuNlM5QDJizszNMUPTRW5ITVJ?
LB1047-RCCNVfVcJd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3j0cWlEPTB;MD6yOFQyKM7:TR?=MXTTRW5ITVJ?
CTB-1M3PmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LheGlEPTB;MD6yOFQ6OyEQvF2=MUnTRW5ITVJ?
A3-KAWM1vGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTBwMkWzOFEh|ryPMlz5V2FPT0WU
SF126MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\IPGlEPTB;MD6yOVM5OyEQvF2=NUPqWo82W0GQR1XS
KARPAS-422Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXr5fVJXUUN3ME2wMlI2PDN3IN88US=>NWHyeot5W0GQR1XS
MEG-01NF\qTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PWe2lEPTB;MD6yOVY4OyEQvF2=NUe0VYZMW0GQR1XS
NCI-H209M2XzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPLflFUUUN3ME2wMlI3Ozd2IN88US=>NU[wSmJoW0GQR1XS
SBC-1M2\oOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HQSWlEPTB;MD6yOlUh|ryPNVW1d5h7W0GQR1XS
K5MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\3elhKSzVyPUCuNlY6QDRizszNNGe5bXJUSU6JRWK=
QIMR-WILM{PtWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPhTWM2OD1yLkK3NVU2KM7:TR?=MV7TRW5ITVJ?
NMC-G1NIO2bXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH[yV4ZKSzVyPUCuNlgzOTdizszNM4S5ZXNCVkeHUh?=
IST-MES1NWPwR5BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfDVXpKSzVyPUCuNlkzOzhizszNNEKwVYVUSU6JRWK=
SW684MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYr1ZopoUUN3ME2wMlMxODR5IN88US=>MWrTRW5ITVJ?
MV-4-11MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTBwM{C3PFgh|ryPNWXvZ4gyW0GQR1XS
LAN-6M3PkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVztboxIUUN3ME2wMlMyPTd{IN88US=>MnO5V2FPT0WU
RH-1NF3oe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXMUVJKSzVyPUCuN|E5PzFizszNNVjIb4JNW0GQR1XS
CP66-MELNWXVfmYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTBwM{G4O|gh|ryPNX[1S4o4W0GQR1XS
EC-GI-10M4\oTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTBwM{K5PFch|ryPM1TwU3NCVkeHUh?=
GDM-1NXnqN4ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXYd2RlUUN3ME2wMlM{ODV7IN88US=>MmTiV2FPT0WU
IST-SL1Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTBwM{S5NVQh|ryPMlrwV2FPT0WU
KMOE-2NYfJXINtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTBwM{WxO|Uh|ryPMX7TRW5ITVJ?
OS-RC-2NHPuZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfrZnVPUUN3ME2wMlM2PTR2IN88US=>MUPTRW5ITVJ?
HDLM-2NFHJVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrNc5FIUUN3ME2wMlM4QDF2IN88US=>NW\zOVlUW0GQR1XS
DSH1NUPC[VNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\sTWM2OD1yLkO4OlMyKM7:TR?=MXTTRW5ITVJ?
LS-1034NXrTSFFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXmR3VRUUN3ME2wMlM5QTV2IN88US=>NUjhUnlKW0GQR1XS
LB373-MEL-DM{nCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrxTWM2OD1yLkO5NVk4KM7:TR?=MlvaV2FPT0WU
GOTOM13FUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTBwNEKxNVgh|ryPNFHrW5VUSU6JRWK=
MRK-nu-1NWmxU5hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DBcWlEPTB;MD60NlIxPSEQvF2=M1XhT3NCVkeHUh?=
SK-MM-2MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\kTWM2OD1yLkSzOFQzKM7:TR?=MkHDV2FPT0WU
BOKUMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DQeWlEPTB;MD60N|c6OiEQvF2=MUDTRW5ITVJ?
NOMO-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlu1TWM2OD1yLkSzPFYh|ryPNHr5cpNUSU6JRWK=
J-RT3-T3-5MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DpWGlEPTB;MD60OFg4QCEQvF2=NUGxNm56W0GQR1XS
COLO-668NFTnb3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTBwNEW2Olgh|ryPNUfTUoxvW0GQR1XS
SF539NGPieINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7HToxKSzVyPUCuOFg3QDRizszNMUPTRW5ITVJ?
LB2518-MELMoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHCc2pKSzVyPUCuOFk4ODNizszNMYXTRW5ITVJ?
TE-441-TMoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjTVoNwUUN3ME2wMlUxOTJizszNMoqwV2FPT0WU
MDA-MB-134-VIMlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTBwNUC5NlEh|ryPNF3YeXlUSU6JRWK=
SCC-3MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTBwNUG4O|Mh|ryPMVLTRW5ITVJ?
KLENIP2ZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDLNGRKSzVyPUCuOVIyPzFizszNMXPTRW5ITVJ?
LB2241-RCCMkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTBwNUK1NlUh|ryPM2jQUnNCVkeHUh?=
NCI-H1417MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrkXFNKSzVyPUCuOVM1OzVizszNNVewN|ZqW0GQR1XS
NCI-H2081MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLrTWM2OD1yLkW4OlEyKM7:TR?=MWTTRW5ITVJ?
NCI-H1522NXPxTI8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXwTWM2OD1yLkW5N|g{KM7:TR?=MknMV2FPT0WU
NCI-H889MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTBwNUm4OFQh|ryPNI\tUHNUSU6JRWK=
CGTH-W-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nmdGlEPTB;MD62NFc2PSEQvF2=NYT0TWg1W0GQR1XS
EB-3NInCNGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTBwNkGxOVMh|ryPMWTTRW5ITVJ?
D-336MGM1jzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTBwNkG3PVEh|ryPMUjTRW5ITVJ?
LC-1FMkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTBwNkK1PVIh|ryPNVL5OXo1W0GQR1XS
MHH-NB-11MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{S5WmlEPTB;MD62N|gxOSEQvF2=MlexV2FPT0WU
SK-N-FINX3hR5RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXoeFJKSzVyPUCuOlM6OSEQvF2=MXfTRW5ITVJ?
NCI-H69NIPUNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTBwNkS4O|kh|ryPMoDWV2FPT0WU
SCHMnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\2VYdKSzVyPUCuOlYxOjNizszNNGSySYRUSU6JRWK=
LS-513M1zUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYO1WY9vUUN3ME2wMlY4OjV7IN88US=>MmO1V2FPT0WU
CP67-MELMmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVnCe2lMUUN3ME2wMlY4PTl4IN88US=>NHziXYFUSU6JRWK=
GCIYNYPC[|NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nqOWlEPTB;MD63NFM3OyEQvF2=NYX2enZKW0GQR1XS
SHP-77NYH2eXRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlG0TWM2OD1yLkewO|M1KM7:TR?=MWPTRW5ITVJ?
EHEBMmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nVVWlEPTB;MD63NVg2PCEQvF2=NInISXBUSU6JRWK=
D-247MGM1PRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXaNHlKSzVyPUCuO|MzOzJizszNM{jpcXNCVkeHUh?=
RajiNYTOU4Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILoV2lKSzVyPUCuO|Q6QDlizszNNWrZ[Vc6W0GQR1XS
MPP-89MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTBwN{W5O|gh|ryPM4LpZnNCVkeHUh?=
EKVXMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnvTWM2OD1yLke5NFc{KM7:TR?=NULGOmFMW0GQR1XS
HCC2218MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rWUmlEPTB;MD63PVE{OSEQvF2=M1rDN3NCVkeHUh?=
KNS-81-FDM3vLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2raW2lEPTB;MD64NVAyOSEQvF2=MULTRW5ITVJ?
HCC2157MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTBwOES5OVEh|ryPMmnKV2FPT0WU
BT-474M3vVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HyemlEPTB;MD64PFg2PCEQvF2=MlOzV2FPT0WU
NCI-H748NWHuRXR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;VNI1KSzVyPUCuPVEzKM7:TR?=MXHTRW5ITVJ?
EW-24MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjGS4JCUUN3ME2wMlkzODB{IN88US=>MlfMV2FPT0WU
D-263MGNYDsT5llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkezTWM2OD1yLkm0OVEzKM7:TR?=MVnTRW5ITVJ?
OMC-1MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MornTWM2OD1yLkm2N|c{KM7:TR?=NYLJOJlrW0GQR1XS
NCI-H2196M3ja[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jKXWlEPTB;MD65O|c4PyEQvF2=NFHqU4pUSU6JRWK=
HAL-01MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\qN2hKSzVyPUCuPVk5PzJizszNMVnTRW5ITVJ?
NCI-H2107NX3VUGNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF64clNKSzVyPUGuNFE5PTRizszNMX\TRW5ITVJ?
LB996-RCCNEf3OlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrreWZIUUN3ME2xMlA5ODVzIN88US=>NFXIcI9USU6JRWK=
NCI-H1395M1j1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXrVVlBiUUN3ME2xMlExPjdizszNNXTwXFVrW0GQR1XS
CHP-126MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zIfGlEPTB;MT6xOlE6QSEQvF2=MXvTRW5ITVJ?
NB69MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{flXmlEPTB;MT6yOlE1QCEQvF2=MX;TRW5ITVJ?
CAS-1M3PCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTFwM{SyN|Eh|ryPM{D6R3NCVkeHUh?=
JVM-3MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrP[VJTUUN3ME2xMlQ4QDV3IN88US=>M3ztbXNCVkeHUh?=
DMS-153MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTFwNUe2O|Qh|ryPNU\XTmlQW0GQR1XS
SK-MEL-2M2nLe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTFwN{G3PFkh|ryPNGjMTWFUSU6JRWK=
NCI-H1155NHuzNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;MWG9vUUN3ME2xMlc{Pjd4IN88US=>MnnFV2FPT0WU
NCI-H1092Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\4VIpKSzVyPUGuO|YyQDJizszNNHXRTWdUSU6JRWK=
LU-165M3XSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NES1XopKSzVyPUGuPFY1PzZizszNM1XVd3NCVkeHUh?=
HL-60M13lbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrNTWM2OD1zLkm5PVA5KM7:TR?=NHK2XGtUSU6JRWK=
REHMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NISyOXZKSzVyPUKuNFA2QDJizszNMl3kV2FPT0WU
JVM-2NVrkcpFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXqSppzUUN3ME2yMlA3OTN3IN88US=>MmGwV2FPT0WU
MN-60M2rBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DCcWlEPTB;Mj6xO|MxQCEQvF2=M4jJd3NCVkeHUh?=
SCC-15MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2q0NGlEPTB;Mj6yNFI4KM7:TR?=NIm1dHFUSU6JRWK=
SNU-C1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2Plb2lEPTB;Mj6yNVM1OyEQvF2=NGixfJhUSU6JRWK=
SK-MEL-1M2TGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrmWGtmUUN3ME2yMlMzODR5IN88US=>M1;nSnNCVkeHUh?=
TGWM3rld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTJwM{WwNlch|ryPMnvzV2FPT0WU
CA46MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HwWmlEPTB;Mj63OVk3PyEQvF2=MVLTRW5ITVJ?
NCI-H23MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXlTWM2OD1{LkiwO|kyKM7:TR?=MoDiV2FPT0WU
MMAC-SFM4Tmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmnYTWM2OD1{Lki2OlI5KM7:TR?=NYPjU5ZWW0GQR1XS
NCI-H2171MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTNwMEO0OFgh|ryPNGHjeI1USU6JRWK=
A704M1v4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXrmXVVjUUN3ME2zMlE1OTl2IN88US=>NITSOpFUSU6JRWK=
DBNHTU[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHq0dG5KSzVyPUOuNlU2PzZizszNM3LTXXNCVkeHUh?=
NCI-H719MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjmcGg4UUN3ME2zMlMxOzh2IN88US=>MUHTRW5ITVJ?
MC-CARNXvrNlR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHf2W2ZKSzVyPUOuOVQ5OTdizszNNHnnZpRUSU6JRWK=
SIMANUXxUox3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXr5cYp3UUN3ME2zMlU5PDF4IN88US=>M1vDfXNCVkeHUh?=
SW872M3[3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3nTWM2OD1|Lke4NVAyKM7:TR?=MVfTRW5ITVJ?
HCC1187NVr1VJpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTNwN{izNVUh|ryPMUfTRW5ITVJ?
EW-13MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFHJOVNKSzVyPUOuPFM1OTdizszNNEfwXolUSU6JRWK=
NCI-SNU-1Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPYZ4dKSzVyPUSuNlE6QTlizszNNWDocohuW0GQR1XS
NCI-H226MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\HTWM2OD12LkOzOlA3KM7:TR?=NInzR4tUSU6JRWK=
RPMI-8866NEPlXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDvbm1KSzVyPUSuN|YxOjlizszNMVjTRW5ITVJ?
OCI-AML2MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DKUmlEPTB;ND61OVI{KM7:TR?=MYnTRW5ITVJ?
LU-65NGjMbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTZTWM2OD12LkmzNFM{KM7:TR?=MWrTRW5ITVJ?
SK-N-DZM3zjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEm3fJFKSzVyPUWuOlM1PjVizszNNFPHXZZUSU6JRWK=
NB14MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PoemlEPTB;NT65O|E{PSEQvF2=NWDtT25bW0GQR1XS
COLO-829NXjGZ3BsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTZwM{OzOVkh|ryPNIWxemJUSU6JRWK=
MHH-CALL-2MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HacWlEPTB;Nj61NVUxQCEQvF2=NVnB[2NjW0GQR1XS
NCI-H1770M165emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTZwNk[5NFQh|ryPNH3JW3lUSU6JRWK=
ECC4MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHjTWM2OD14LkiyNVc6KM7:TR?=MUnTRW5ITVJ?
A498MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLwOpJKSzVyPU[uPFcyQTJizszNNXrUXJZiW0GQR1XS
DMS-79MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\u[WlEPTB;Nz6wOFUyOiEQvF2=MlTJV2FPT0WU
P30-OHKMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEGy[m1KSzVyPUeuNlE6ODZizszNMXzTRW5ITVJ?
D-502MGNF7acIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XE[2lEPTB;Nz65PFM3KM7:TR?=M3nidXNCVkeHUh?=
RCC10RGBM3HMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TZSmlEPTB;OD6wOlI5KM7:TR?=Mny2V2FPT0WU
U-698-MMkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4frZWlEPTB;OD6yPVIzPiEQvF2=MUXTRW5ITVJ?
BB49-HNCNVX4Z4xZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mom1TWM2OD17LkSyNlY2KM7:TR?=M3rl[nNCVkeHUh?=
ES1MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MorOTWM2OD17Lk[4PVU3KM7:TR?=MlTJV2FPT0WU
MFM-223NWfmbpp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mli4TWM2OD1zMD65PVI4KM7:TR?=NWTJOINuW0GQR1XS
C2BBe1Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTFzLkO1NlMh|ryPMm\xV2FPT0WU
EB2NFixT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjadW5KSzVyPUGyMlY5QDFizszNM1nM[XNCVkeHUh?=
C8166MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;CZ5dKSzVyPUGzMlg{ODNizszNM3HvTnNCVkeHUh?=
ES3M4WxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGK5V2VKSzVyPUGzMlk6PzdizszNM3XCW3NCVkeHUh?=
NCI-H1650M3S2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\4R|BqUUN3ME2xOk4{PzZ3IN88US=>MnTuV2FPT0WU
Mo-TMmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTF5LkSwNlkh|ryPMWDTRW5ITVJ?
NB7NE[wPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2njbGlEPTB;MUeuO|Q3PyEQvF2=M2\GWHNCVkeHUh?=
ES7NEixeZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fiWmlEPTB;MUmuOVUxPyEQvF2=M17LdHNCVkeHUh?=
ES5M3vsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPDTWM2OD1{MT63OlcyKM7:TR?=MYrTRW5ITVJ?
MSTO-211HMnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M163eGlEPTB;MkGuPFg2QCEQvF2=MYTTRW5ITVJ?
U-87-MGNX;rfoZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmiyTWM2OD1{NT6xPVY3KM7:TR?=Mn;IV2FPT0WU
THP-1M{fubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTJ7LkeyNFEh|ryPNIPS[mtUSU6JRWK=
NB10NX3CVo5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn25TWM2OD1|MD6yOlk1KM7:TR?=Ml36V2FPT0WU
NH-12MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTN|LkKwNVch|ryPNV\RW2VmW0GQR1XS
COLO-824M1HpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\WWGlEPTB;M{SuNVAxPiEQvF2=MmLmV2FPT0WU
SKM-1M1vyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWrHUJl2UUN3ME2zO{45PDJ{IN88US=>NVnXR5E6W0GQR1XS
NCI-H1838MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHqOmtKSzVyPUO4MlM4QTdizszNMmf5V2FPT0WU
RLM4Pocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTN7LkK0O|ch|ryPMkm5V2FPT0WU
COLO-800NVTp[m94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmK4TWM2OD12MD6wO|c{KM7:TR?=M{TuRXNCVkeHUh?=
KG-1M1fhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYK2[XNHUUN3ME20NE45QTV3IN88US=>MUHTRW5ITVJ?
TURM3rJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTRzLk[zPVkh|ryPM{npZXNCVkeHUh?=
LNCaP-Clone-FGCMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTRzLkmwNVch|ryPMmHFV2FPT0WU
NCI-H322MM4ntXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzmR2piUUN3ME20Nk42QTh2IN88US=>MnfzV2FPT0WU
LNCaP NVe5UGh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTlzLkOgcm0>MVWyOVUxPTF5NB?=
C4-2M2jZc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13FZmlEPTB;ODDuUS=>MoToNlU2ODVzN{S=
JURKATNGPT[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfaU2czPCCqMofqTWM2OD12MU[uOlYhdk1?NIfYOGgzPDVzOUm5OS=>
MOLT-4NXznNW5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYOyOEBpMXzJR|UxRTJ6NUOuOUBvVQ>?M4rKXlI1PTF7OUm1
REHMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXToOIMyOjRiaB?=Mni2TWM2OD1{OEeuOlghdk1?M2LQO|I1PTF7OUm1
NALM-6NF6zbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHwe|UzPCCqM2XVSmlEPTB;M{SzN|Ahdk1?MnHMNlQ2OTl7OUW=
RS 4;11NGHQVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWP0endTOjRiaB?=NHrM[YxKSzVyPUWxPU4xPSCwTR?=MV2yOFUyQTl7NR?=
697MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7Nb4ozPCCqNUj5cYVPUUN3ME2yNVA4NjFibl2=NF;DbFYzPDVzOUm5OS=>
SIL-ALLM2PWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVqyOEBpMYnJR|UxRTF7OT63O{BvVQ>?MonmNlQ2OTl7OUW=
CEMNX;iXY82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPqNlQhcA>?NVPI[oZkUUN3ME21Nk4yQCCwTR?=MVGyOFUyQTl7NR?=
P12NUfNNZRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV6yOEBpNUPxNI5ZUUN3ME2zPU4zPyCwTR?=M4nlNFI1PTF7OUm1
NALM-16M2D2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFGy[oYzPCCqNXLFe4tJUUN3ME25Ok4zQCCwTR?=MWSyOFUyQTl7NR?=
JURKATM2HlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDhd5h{PDhiaB?=MnPYTWM2OD1zND64OEBvVQ>?M3zhfFI1PTF7OUm1
MOLT-4M13NbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DuXFQ5KGh?M2[4fWlEPTB;Mk[uOkBvVQ>?M{HJOFI1PTF7OUm1
REHNYrmd4pzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\OTpE1QCCqNELLdmpKSzVyPUS0MlcyKG6PMX:yOFUyQTl7NR?=
NALM-6NEX3U2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHBbYg1QCCqNFS1OWZKSzVyPUKzMlI3KG6PM2G2fVI1PTF7OUm1
RS 4;11NEP2S4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV72enNPPDhiaB?=Ml3TTWM2OD1zNkSuNlghdk1?NYfZSGtsOjR3MUm5PVU>
697MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnWOFghcA>?NGXJS5hKSzVyPUOwOU4{KG6PMlriNlQ2OTl7OUW=
SIL-ALLMlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jzVFQ5KGh?NVjD[pV3UUN3ME23OE43OiCwTR?=MonhNlQ2OTl7OUW=
CEMM3jN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWG5WGxtPDhiaB?=M1OxdmlEPTB;MkSuOVUhdk1?MVuyOFUyQTl7NR?=
P12MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\z[FQ5KGh?NV3ONolzUUN3ME2xPE41PiCwTR?=NGHTNHozPDVzOUm5OS=>
NALM-16M3zJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXW0PEBpMk\XTWM2OD14Mz6yOEBvVQ>?MVqyOFUyQTl7NR?=
JURKATMmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3roOFczKGh?MnfKTWM2OD1|Lk[1JI5OMWCyOFUyQTl7NR?=
MOLT-4M1PvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;hZ|czKGh?Mlq4TWM2OD15LkO5JI5OMnL0NlQ2OTl7OUW=
REHNHLzcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\RO|IhcA>?MnjrTWM2OD1zNj6wNUBvVQ>?NYPWZnpVOjR3MUm5PVU>
NALM-6NUG2RmJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXy1RZRUPzJiaB?=NITmVnBKSzVyPUGuO|ghdk1?MUmyOFUyQTl7NR?=
RS 4;11MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrEO|IhcA>?MV;JR|UxRTRwM{igcm0>NFuw[G4zPDVzOUm5OS=>
697NUf6eJFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPXVZE4OiCqMWnJR|UxRTd2LkK4JI5ONYnaNokyOjR3MUm5PVU>
SIL-ALLM173XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrFO|IhcA>?MWrJR|UxRTdwMjDuUS=>MYqyOFUyQTl7NR?=
CEMM2O2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGGzO3g4OiCqNX7NV2tHUUN3ME21MlQzKG6PNIHQZ5kzPDVzOUm5OS=>
P12M2DOS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInuXZY4OiCqMnjVTWM2OD14LkO3JI5OMUOyOFUyQTl7NR?=
NALM-16Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnUO|IhcA>?M1;JWWlEPTB;N{euO|Mhdk1?MW[yOFUyQTl7NR?=
Y79NWXNNFJ2SXCxcITvd4l{KEG|c3H5M3nLW|EuPTBibl2=NUPze4ZzOTJxMkSgbC=>NVXLNW1kTE2VTx?=MUPpcoR2[2WmIHHwc5B1d3OrczD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nliSGS=MoC3NlQ{PjZ4NkW=
WER-Rb-1NUnVcGRYSXCxcITvd4l{KEG|c3H5NV;1[WJjOS13MDDuUS=>M{jwcFEzNzJ2IHi=MXXEUXNQNV\NRppkcW6mdXPl[EBieG:ydH;zbZMhf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGhVM1jxUlI1OzZ4Nk[1
G7MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVOzUoFoUUN3ME2zMlMhdk1?NF31SmMzPDJyNEezNy=>
G166NIW3Z5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTdwMDDuUS=>MlHMNlQzODR5M{O=
CB660M2HnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTZwNDDuUS=>MXeyOFIxPDd|Mx?=
CB1117MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHnPXBKSzVyPUG1MlYhdk1?NIjLZ3IzPDJyNEezNy=>
KB-3-1MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7MfY1xUUN3ME2xMlQ5KMLzIECuOVMhdk1?NV\5bpduOjN7NkK0OFU>
KB-8-5-11MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXr2OZZPUUN3ME21MlAyKMLzIEKuNFEhdk1?NUPFbIpVOjN7NkK0OFU>
KB-C-1NXHSV3p5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDyPXBKSzVyPUG2Mlc3KMLzIESuOVEhdk1?NXe3[JBnOjN7NkK0OFU>
KB-V-1MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXKOZpKSzVyPUK4NU4zPCEEsTCzNU42PyCwTR?=Mk[0NlM6PjJ2NEW=
OVCAR-8NVTielNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4Xa[mlEPTB;Nz6xPUDDuSB|Lk[wJI5OM1exd|I{QTZ{NES1
NCI-ADR-RESMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHW0NYJKSzVyPUGyO|MvOzBiwsGgNVkyNjJyIH7NM3XNc|I{QTZ{NES1
MCF7NFrDOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLpTm1KSzVyPUWuNVEhyrFiMT60O{BvVQ>?M3TMTVI{QTZ{NES1
MCF7-FLV1000NYfMb3BjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTN7Mz6xPEDDuSB5ND64N{BvVQ>?MYGyN|k3OjR2NR?=
S1NFjSV|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jvcGlEPTB;MkSuN|AhyrFiND63OUBvVQ>?MUiyN|k3OjR2NR?=
S1-M1-80M1qxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoC5TWM2OD1{NkGuNFYhyrFiNEiuNlUhdk1?NHvUR28zOzl4MkS0OS=>
CORL-23/PNYTrPZpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzSUW81UUN3ME20MlM5KMLzIEGuNlUhdk1?MVOyN|k3OjR2NR?=
CORL-23/RM1PQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvCcmNKSzVyPUWuNVYhyrFiMT64N{BvVQ>?M3zUOlI{QTZ{NES1
NIH3T3MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTRyLk[wJOKyKDRwOUegcm0>NFjSW4QzOzl4MkS0OS=>
NIH3T3-G185M13TXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUW5Z4N{UUN3ME2yOFE{NjRyINMxJFQzOy54NjDuUS=>NFPHW5MzOzl4MkS0OS=>
pcDNA-HEK293NG[yR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4r3cGlEPTB;Mj63OUDDuSByLk[3JI5ONVfXfJNbOjN7NkK0OFU>
MDR19-HEK293MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLDXXppUUN3ME24OU42OCEEsTCxN{43PyCwTR?=MoryNlM6PjJ2NEW=
R482-HEK293MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;l[5A{UUN3ME2yOU46PyEEsTC0Mlk2KG6PNGX1bIUzOzl4MkS0OS=>
MRP1-HEK293Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTJwOUmgxtEhOS52OTDuUS=>NUnLSWZbOjN7NkK0OFU>
SF188MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1ryXVExNTFyMDDuUS=>NH7heoQzPC17NjDoNWCySVFYTE2VTx?=MXXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLTDk[ZBm\GWwdDDtZY5v\XJ?MX[yN|g5PzZ2NR?=
T98GM2nNPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELoWVYyOC1zMECgcm0>M4jCVlI1NTl4IHi=MWHEUXNQNWLRPWc4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdi1iZHXw[YRmdnRibXHucoVzMlu4NlM5QDd4NEW=
DU145NGT5bFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrpUG5FVVORNIWxUVdKSzVy4pk8OlAhdk1?NGD3TIwzOzh6NESyPC=>
LNCaP NFTPdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7EUXNQM17QWmlEPTEkiMy3OUBvVQ>?NXfZSVRJOjN6OES0Nlg>
PC3M3\MfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2r0emROW09?M2LBZWlEPTEkiMyxO|Uhdk1?MYeyN|g5PDR{OB?=
RT4Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfJWHlKSzVyPUK3MlIyKG6PNYLrUGNZOjN5OUK2N|k>
5637M3fucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\OemV6UUN3ME20OU41PyCwTR?=NWTl[nRHOjN5OUK2N|k>
T24MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NImxR5NKSzVyPUe5MlEzKG6PM2\3RlI{Pzl{NkO5
MCF7 M{\DUGZ2dmO2aX;uJGF{e2G7M3jzT|ExOCCwTR?=NFXDdngyKGh?MoTQSG1UVw>?M3zkbZJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZtMgS5Jm[jFuwrDT[4syNMLiUIOyMOKhW2W{cHnuZVMtKGGwZNMgW4l{eDJ?NXjyTYduOjN5N{CyOFQ>
KB-V1 M2DqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3X3[WlEPTB;Mz65NkDPxE1?MoHqNlM2QTNzOU[=
Hec50coNX;rUHBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTVibl2=MkjoNlMyPDZ4OEe=
MDA-MB-468MmDLRZBweHSxc3nzJGF{e2G7Mmq4NU82NzFyIH7NMYGyOE81QC95MjDoNXPMXoZGTE2VTx?=NX7kbXp{cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>MnLlNlMyPDR{OUS=
MCF10ANGDGXXBCeG:ydH;zbZMhSXO|YYm=NUfxOnNVOS93L{GwJI5ONU\4e21HOjRxNEivO|IhcA>?MkK4SG1UVw>?MnWxbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=NGnnR5IzOzF2NEK5OC=>
Huh-7MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUKxM|ExNzFyMD:xNFAxKG6PNFK2b2o1QCCqMlHN[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBld3OnLXTldIVv\GWwdHz5MX2yNlc1PTV6Nx?=
Daoy M1HrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnDT|ZqOS56N{WtNlQxKG6PMX63NkBpNELrNVBFVVORM{X3e2lEPTB;NTDuUS=>NHTKc5AzOjN7MEK3PS=>
ONS-76MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rHVVEvQDd3LUK0NEBvVQ>?MnLGO|IhcA>?MUjEUXNQNFTJbVlKSzVyPUeuOUBvVQ>?NWnMOZRlOjJ|OUCyO|k>
SUM 149MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVuwMVExOCCwTR?=M1zHNlczKGh?NV:2cXh2cW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFzNHHXdGozOjNyOUmzPS=>
MDA-MB-231NU\tWWt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXN[YMxNTFyMDDuUS=>NWrqbHVIPzJiaB?=MXPpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=NGXmUFQzOjNyOUmzPS=>
HR5NFW2XXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofwNE0yODBibl2=MkfIO|IhcA>?NV6zTIhncW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFzMXOyNlMxQTl|OR?=
BT-474-M1NVvnOZp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rSfFAuOTByIH7NM3rVblczKGh?NHe5UIRqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI>M1[4SVIzOzB7OUO5
AU565NIPl[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfUVmMxOC1zMECgcm0>NUXpUHo1PzJiaB?=NFTkenRqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI>MlyzNlI{ODl7M{m=
T47DMmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDybpgxNTFyMDDuUS=>NGfBVGI4OiCqMn7nbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHyM2fvV|IzOzB7OUO5
MCF7NEnyT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXPRXkxNTFyMDDuUS=>MXy3NkBpMnP6bY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHyNX24[GNrOjJ|MEm5N|k>
HCT116p53(+/+)MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYGxNE0yODByIH7NMVKyOE81QCCqNIDWcndqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h[2:vcHzleIVtgSCjdDCyOUBvVQ>?MnzjNlIzPjJzN{G=
HCT116p53(-/-)M3nJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXz[GtuOTBvMUCwNEBvVQ>?NEDpUWwzPC92ODDoNYjycoc4cW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHliYYSgNlUhdk1?M2W4RVIzOjZ{MUex
HeLa M4Ll[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlzwNVAuOTByIH7NMWq0PEBpM1TaS2ROW09?M365dWlEPTB;NUKuPUBvVQ>?M1PGWFIzODhyMkO1
HeLa M4H5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jYVFExNTFyMDDuUS=>M4i1VlczKGh?M2Ds[WROW09?NVfMc5N3UUN3ME21NE42KG6PM2nNZ|IzODhyMkO1
GBCMlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LheVczKGh?Mk\kTWM2OD1zND63PEBvVQ>?NFfCclkzOTl4NUezPS=>
GB-CL-1M3TDO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nlVFczKGh?M4DaVmlEPTB;NT6yNkBvVQ>?M3XOWFIyQTZ3N{O5
Mz-ChA-2M4XCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV63NkBpNH\zSpNKSzVyPUOuN|Ehdk1?NFzOSHMzOTl4NUezPS=>
TGBC1-TKBMonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYSxOFQhcA>?NHT6ZmxKSzVyPU[uO|Ihdk1?NG\UNXQzOTl4NUezPS=>
WittierM4PNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXX1T2RRPzJiaB?=MmnBTWM2OD1|LkK2JI5OMljXNlE6PjV5M{m=
H-1NYr2TFN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX:3NkBpMUHJR|UxRTlwNUSgcm0>NFvvWVgzOTl4NUezPS=>
HuH-28NYP2VmE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3roSlczKGh?MUjJR|UxRTFzLkG5JI5ONWLZc5hCOjF7NkW3N|k>
NECMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIS3WFE4OiCqMlPXTWM2OD17Lkm4JI5OM1T6eFIyQTZ3N{O5
REBM1X4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vPclczKGh?M4TZ[2lEPTB;MUOuOVEhdk1?M330elIyQTZ3N{O5
CC-LP-1MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LMSFczKGh?NUm2XVMyUUN3ME21Mlg1KG6PM2PzUVIyQTZ3N{O5
CC-SW-1MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{n3RVczKGh?NXm1NnJLUUN3ME25MlU2KG6PM37WOFIyQTZ3N{O5
EGI-1M{n5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXG3NkBpM3vDcGlEPTB;MUCuO|Ihdk1?MWeyNVk3PTd|OR?=
Sk-ChA-1NF3XPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorsO|IhcA>?NEDuRWVKSzVyPUG3MlIhdk1?M17Jb|IyQTZ3N{O5
TFK-1NHzwO|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUGwUnNQPzJiaB?=NYDofVJ{UUN3ME2xN{41PSCwTR?=MV6yNVk3PTd|OR?=
786-OM3nNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTyR2tpPS16MDDuUS=>M4izW|k3KGh?MVXIR4w>NUXFVpRpe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7NM2HmTFIyPjR{M{e0
A498MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWC1MVgxKG6PMl6xPVYhcA>?NHzrVItJS2x?NH\UN4p{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2=MlX2NlE3PDJ|N{S=
ACHNNEfBOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jWflUuQDBibl2=MWm5OkBpNHuwc5lJS2x?MkLCd5VxeHKnc4Pld{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIFnDOVDDqH[jbIXld{Bw\iB{IITvJFIxKG6PNXHlZnV[OjF4NEKzO|Q>
Caki-1NEPvSIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXnUXpMPS16MDDuUS=>MoS3PVYhcA>?NYD4[|VuUEOuM1j2V5N2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?=NUnjR4xCOjF4NEKzO|Q>
SN12CNETTNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWW1MVgxKG6PM2\HS|k3KGh?MlrKTGNtNYO3OlVTe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7NNUHveIlnOjF4NEKzO|Q>
HMC-1.1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XKfFEuOTByMDDuUS=>MYq3NkBpNHzZd5dqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmV?NXjWN49OOjF{NEKxPFk>
HMC-1.2NI[zNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWSxMVExODBibl2=NH3oXXo4OiCqMYrpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoU>MYOyNVI1OjF6OR?=
C2NGW4WZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVqxMVExODBibl2=M{nUXFczKGh?Mn3wbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5mMWGyNVI1OjF6OR?=
CHP-212M1;rTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVqxMVEzPSCwTR?=NXPvUVhWOjRvMUKwJIg>MkXZbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=NFHkU4ozOTF4OUK0Ni=>
IMR-32NF\nZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\jNVMyNTF{NTDuUS=>MV2yOE0yOjBiaB?=MXfpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nMVuyNVE3QTJ2Mh?=
KellyMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV6xMVEzPSCwTR?=M{XIS|I1NTF{MDDoNXXYfpZZcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>NGThdI0zOTF4OUK0Ni=>
SH-EPMnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX6xMVEzPSCwTR?=NI\YV4IzPC1zMkCgbC=>MWXpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nMoDSNlEyPjl{NEK=
SH-SY5YM1fpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjBUm8yNTF{NTDuUS=>MVKyOE0yOjBiaB?=NETYSXFqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7lM1PCT|IyOTZ7MkSy
SK-N-ASMl72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWixMVEzPSCwTR?=NHPVeIozPC1zMkCgbC=>M1nLOIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=MX[yNVE3QTJ2Mh?=
SK-N-BENYnaVldDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLuXZJzOS1zMkWgcm0>MljyNlQuOTJyIHi=NE\sTm1qdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7lM3myflIyOTZ7MkSy
KG1NXvvVINlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTPNU8yOC9zMECgcm0>MnvlO|IhcA>?NHv0NohFVVORM2eyWIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=M1WwWlE6PDV6M{W4
U937NVrWNoxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn2yNU8yOC9zMECgcm0>M2LjcFczKGh?M2\t[mROW09?MU\pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nMYmxPVQ2QDN3OB?=
CAL62NHm0SGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;WNE4yNTFyMDDuUS=>NG\0NI84OiCqM1jocGROW09?NGH5d45GSzVyPUGuOEBvVQ>?NGjYdIEyQTJ{M{W1Ny=>
OCUT-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYewMlEuOTByIH7NMomxO|IhcA>?MnvhSG1UVw>?MYHFR|UxRTJwMzDuUS=>Mn7GNVkzOjN3NUO=
8505CMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MonrNE4yNTFyMDDuUS=>MV:3NkBpNX3mc5I5TE2VTx?=M4rp[mVEPTB;Mz6yJI5OMnvLNVkzOjN3NUO=
ACT-1Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17OeFAvOS1zMECgcm0>MYC3NkBpMV;EUXNQMkDySWM2OD13LkSgcm0>MUSxPVIzOzV3Mx?=
SW1736NIXOVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIqxbGExNjFvMUCwJI5OMkHhO|IhcA>?M4DqdGROW09?MUfFR|UxRTVwNjDuUS=>M3my[VE6OjJ|NUWz

... Click to View More Cell Line Experimental Data

In vivo BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. [1]
Features The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.

Protocol(Only for Reference)

Kinase Assay: [1]

Plk1 in vitro kinase assay Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl2, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-33P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.

Cell Assay: [1]

Cell lines HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc.
Concentrations Dissolved in DMSO, final concentrations ~1 μM
Incubation Time 24 and 72 hours
Method Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis.

Animal Study: [1]

Animal Models Female BomTac:NMRI-Foxn1nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells
Formulation Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl
Dosages ~50 mg/kg
Administration Injection i.v. once or twice per week

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Steegmaier M, et al. Curr Biol, 2007, 17(4), 316-322.

[2] Nappi TC, et al. Cancer Res, 2009, 69(5), 1916-1923.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-06-25)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT00526149 Completed Breast Cancer|Endometrial Cancer|Head and Neck Cancer|Melanoma (Skin)|Ovarian Cancer|Sarcoma European Organisation for Research and Treatment of Cance  ...more European Organisation for Research and Treatment of Cancer - EORTC July 2007 Phase 2
NCT02215044 Terminated Pancreatic Neoplasms Boehringer Ingelheim June 2007 Phase 1
NCT00412880 Completed Carcinoma, Small Cell Boehringer Ingelheim January 2007 Phase 2
NCT02211833 Completed Carcinoma, Non-Small-Cell Lung Boehringer Ingelheim October 2006 Phase 1
NCT00701766 Completed Leukemia, Myeloid, Acute Boehringer Ingelheim October 2006 Phase 2

view more

Chemical Information

Download BI 2536 SDF
Molecular Weight (MW) 521.66
Formula

C28H39N7O3

CAS No. 755038-02-9
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 21 mg/mL (40.25 mM)
Ethanol 100 mg/mL (191.69 mM)
Water <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 15 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (R)-4-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide

Customer Product Validation(10)


Click to enlarge
Rating
Source Cancer Cell 2010 18, 641–654. BI 2536 purchased from Selleck
Method Immunohistochemical analysis
Cell Lines SCID mice
Concentrations
Incubation Time
Results Control tumors grow exponentially, whereas genetic ablation of Cdc20 results in complete tumor regression in about 10 days. In comparison, treatment with taxol, vincristine, and BI2536 only induces partial responses ( Figure C). In agreement with the data observed in vitro, immunohistochemical analysis of samples taken 3 days after the first treatment indicates lack of proliferation (as measured by BrdU incorporation) and massive apoptosis in Cdc20 null cells, whereas all other samples maintain significant levels of proliferation and reduced apoptotic markers ( Figure D)

Click to enlarge
Rating
Source Nat Cell Biol 2011 13, 1265-71. BI 2536 purchased from Selleck
Method cold-stable assay, Immunological methods
Cell Lines RPE1 cells
Concentrations 40 nM
Incubation Time 45 min
Results To examine whether B56-PP2A attenuates the signalling of kinetochore kinases other than Aurora B, we examined Plk1. Remarkably, wash-in of the Plk1 inhibitor BI2536 also restored K-fibres in B56-PP2A-siRNA cells.

Click to enlarge
Rating
Source Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck
Method Western blot
Cell Lines NB TICs
Concentrations 10-100 nM
Incubation Time 16/24 h
Results The cyclin-dependent kinase inhibitor p21, a newly identified substrate of PLK1, also accumulated in BI 2536-treated NB TICs (Fig. C). Finally, PLK1 kinase activity was inhibited following treatment of NB TICs with BI 2536, as demonstrated by anti-PLK1 immunoprecipitiation followed by in vitro PLK1 kinase assay ( Fig. D)

Click to enlarge
Rating
Source Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck
Method Trypan blue exclusion, Western blot
Cell Lines NB TICs
Concentrations 10/30/100 nmol/L
Incubation Time 24/48/72 h
Results We observed a significant difference in viable cell numbers in BI2536-treated samples, as compared with DMSO (vehicle)-treated cells, at 24 hours posttreatment. The difference became more pronounced with time, such that at 72 hours there were only approximately 20% viable cells following treatment with 10 nmol/L BI 2536 and approximately 2% to 5% viable cells following treatment with 30 and 100 nmol/L as compared with DMSO-treated cells(Fig. A). At 24 hours, BI 2536-treated cells gradually accumulated cleaved PARP, in contrast to DMSO-treated cells, suggesting induction of apoptosis ( Fig. B).

Click to enlarge
Rating
Source Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck
Method Tumor growth assay
Cell Lines NOD/SCID mice
Concentrations 12.5-25 mg/kg
Incubation Time 0-24 d
Results As shown in Figure A,tumor growth was significantly inhibited following administration of the third cycle of BI 2536 therapy. When mice were administered 25 mg/ kg weekly on 2 consecutive days for a total of only 2 cycles, tumor growth was inhibited after the second cycle ( Fig. B)

Click to enlarge
Rating
Source Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck
Method Tumor growth assay
Cell Lines NOD/SCID mice
Concentrations 12.5 mg/kg
Incubation Time 0-60 d
Results We examined a combination of a low dose of BI 2536 (12.5 mg/kg) with a low dose of irinotecan (10 mg/kg), a topoisomerase inhibitor with demonstrated activity in phase II clinical trials in relapsed NB. Single-agent treatment with low-dose of either BI 2536 or irinotecan was comparably efficacious, resulting in significant growth inhibition, as compared with vehicle-treated animals.

Click to enlarge
Rating
Source J Invest Dermatol 2011 131, 1886–1895. BI 2536 purchased from Selleck
Method MTT assay
Cell Lines M14 cell lines, WM-115 cell lines
Concentrations 1-20 nM
Incubation Time
Results Specific inhibition of Plk-1 using the commercially available inhibitor BI 2536 led to a dose- and time-dependent decrease in human melanoma cell viability.

Click to enlarge
Rating
Source J Biol Chem 2012 287(21), 17088-99. BI 2536 purchased from Selleck
Method Cell death assay
Cell Lines HeLa cells
Concentrations 0 -120 nM
Incubation Time 72 h
Results In HeLa cells lacking GRK5, there was an~4.5-fold decrease in the EC50 of BI 2536-mediated cell death (control shRNA, 18.9 ?.2 nM; GRK5 shRNA, 4.1?.1 nM, n = 6, p < 0.05) (Fig. A). Similar to BI 2536, cells lacking GRK5 were ~4.5-fold more sensitive to GSK461364 compared with control cells (EC50 for control shRNA cells, 17.0 ?4.4 nM;EC50 for GRK5-shRNA cells, 3.8 ?0.7 nM, n = 4, p < 0.05).

Click to enlarge
Rating
Source J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck
Method 3D Tumor Growth Assay
Cell Lines PC-3M cells
Concentrations 0-10uM
Incubation Time 7 d
Results Reduction of colony size was observed for a number of established anticancer drugs, and IC 50 values for those reference compounds were determined based on the average area size of the cluster. IC 50 values were determined in two independent experiments and were quite reproducible.

Click to enlarge
Rating
Source J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck
Method 3D Tumor Growth Assay
Cell Lines PC-3M cells
Concentrations 10uM
Incubation Time 7 d
Results Reduction of colony size was observed for a number of established anticancer drugs, and IC 50 values for those reference compounds were determined based on the average area size of the cluster. IC 50 values were determined in two independent experiments and were quite reproducible.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related PLK Products

  • SBE 13 HCl

    SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.

  • Ro-3306

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • CCG-1423

    CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.

  • Rigosertib (ON-01910)

    Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.

  • HMN-214

    HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.

  • GSK461364

    GSK461364 inhibits purified Plk1 with Ki of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

    Features:Demonstrates >390-fold selectivity for Plk1 relative to Plk2 and Plk3.

  • Volasertib (BI 6727)

    Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.

    Features:A high volume of distribution, indicating good tissue penetration, and a long terminal half-life.

  • MLN0905

    MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.

  • Ro3280

    RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

    Features:A selective PLK1 inhibitor. Demonstrates greater potency than BI2536. Potential use in nasopharyngeal carcinomas.

  • NMS-P937 (NMS1286937)

    NMS-P937 (NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

Recently Viewed Items

Tags: buy BI 2536 | BI 2536 supplier | purchase BI 2536 | BI 2536 cost | BI 2536 manufacturer | order BI 2536 | BI 2536 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us